Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
SOURCE NeoStem, Inc.
'/>"/>SOURCE NeoStem, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS2.
AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.3.
Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat4.
Xytis Names Gordon H. Busenbark as Chief Financial Officer5.
PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)6.
Association of Clinical Research Organizations (ACRO) Names Dr. Derek Winstanly Chair-Elect7.
California Cryobank Names Richard Jennings President of FamilyCord Division8.
Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO9.
ParagonRx Names Ellen M. Derrico To Chief Marketing Executive Post10.
Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts11.
NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer